A provisional report from the Surveillance, Epidemiology, and End Results (SEER) Program indicate that the number of people who survive from cancer continues to rise. Considering the nature and effect of prior cancer, which is vital in boosting clinical tests accrual, the generalizability of the outcome acquired from trials, observational research, disease results and the experience of those affected.
The participants, design, and setting of this exercise connected all observations from the entire population-based SEER program of those registered with cancer from 1975 to 2013, and 740,990 persons who were diagnosed with cancer since January 2009 to December 2013. The prevalence of prior cancer cases was categorized by age estimates-below 65 years versus those with over 65 years also using an incident cancer type. Major outcomes and measures prevalence of prior cancer was obtained from the SEER statistics (sequence numbers), that stands for all primary diagnosed tumors in one’s lifetime. Incident cancer was grouped as first or only primary, higher primary or second order based on the same cancer site and the second order based on a different cancer site.
A significant proportion of those diagnosed to have incident cancer in U.S survive prior cancer. These patients do not count in the clinical trials and are underrepresented in observational trials since little information is known regarding their treatment and survivorship requirements. Comprehending the nature and effect of prior cancer is essential to advance clinical tests accrual, disease outcome, and the patient experience.
Erick Lefkofsky, the co-founder of Groupon and a member of Chicago’s most powerful tech figures, has significantly contributed millions of dollars to support cancer research centers. Currently, he is the man behind the startup that is aiming to take a more sophisticated approach in the efforts of curing cancer.
Lefkofsky is now serving Tempus, a health-tech startup that is focused on developing an infrastructure to advance and modernize cancer treatment facilities. The firm has been silently working out of Lightbank-a Chicago located early-stage VC Company founded by Lefkofsky, where he is working as the President. He is also the co-founder of Uptake, which harnesses data science to improve other organizations’ operations and general safety.